Loading…
Loading…
KNOXVILLE, Tenn., July 22, 2026 (GLOBE NEWSWIRE) -- VisiRose, Inc. (“VisiRose” or the “Company”), the clinical-stage ophthalmology subsidiary of Provectus Biopharmaceuticals, Inc. (“Provectus”) (OTCQB: PVCT), a clinical-stage biotechnology company developing pharmaceutical grade rose bengal sodium (“RBS”) active pharmaceutical ingredient (“API”) as a platform therapeutic, today announced it has been selected to present at the Emerging Company Showcase at ESCRS iNovation ® Day 2026, to be held September 11th at Excel London in the United Kingdom.
Peer-reviewed preclinical melanoma research finds Provectus's synthetic small molecule can both stimulate anti-tumor immunity and suppress peripheral immune cells at the same dose. A recently published peer-reviewed medical journal article in Molecular Therapy: Oncology by OncoThAI researchers at the University of Lille in France shows that RBS can be immunostimulatory in tumor cells and immunosuppressive in peripheral immune cells at the same dose.
KNOXVILLE, Tenn., June 30, 2026 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT), a clinical-stage biotechnology company developing pharmaceutical grade rose bengal sodium (“RBS”) active pharmaceutical ingredient (“API”) as a platform therapeutic, and VisiRose, Inc. (“VisiRose”), Provectus's clinical-stage ophthalmology subsidiary, today announced the issuance of U.S. Patent No. 12,661,335, titled “Halogenated Xanthene-Containing Topical Anti-Gram-Positive Bacterial Ophthalmic Composition and Method.” The patent covers a topical eye drop formulation of RBS API for treating Gram-positive bacterial keratitis, including drug-resistant strains such as MRSA and vancomycin-resistant Enterococcus.
New IP covers topical rose bengal sodium ophthalmic composition against MRSA and other resistant Gram-positive bacteria without requiring light activation. VisiRose to hold exclusive ophthalmic license. KNOXVILLE, Tenn. , June 30, 2026 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. ("Provectus" or the "Company") (OTCQB: PVCT), a clinical-stage biotechnology company developing pharmaceutical grade rose bengal sodium ("RBS") active pharmaceutical ingredient ("API") as a platform therapeutic, and VisiRose, Inc.
Under Veripure, Provectus is supplying qualified medical researchers with the same pharmaceutical grade rose bengal sodium API used in clinical trials. Veripure is also a quality benchmark, distinguishing program-associated medical research on PV-10 from research conducted using commercially sourced rose bengal of variable purity and uncharacterized content.
Provectus Biopharmaceuticals, Inc. (PVCT) Shareholder/Analyst Call Transcript
KNOXVILLE, Tenn., June 08, 2026 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced that its 2026 annual stockholder meeting (the “Annual Meeting”), including shareholder meeting activities and a company update, will be accessible by Zoom webinar (the “Webinar”). The in-person meeting will be held on Thursday, June 18, 2026 at Perkins Place Office Building, located at 525 Portland Street, Knoxville, Tenn., beginning at 4:00 p.m. Eastern Time.
Long-term survivors in both oral PV-10 arms showed an absence of gross bladder tumor at necropsy, a finding not observed in any untreated, vehicle-control, or anti-PD-1 monotherapy animal. KNOXVILLE, Tenn.